Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
Isabella C. Glitza Oliva(The University of Texas MD Anderson Cancer Center), Michael A. Davies(AstraZeneca (United Kingdom))
Cited by 75
Related Papers
A novel AKT3 mutation in melanoma tumours and cell lines
|British Journal of Cancer|2008|267